Coherus Oncology, Inc.

Coherus Oncology announced interim clinical data from the TREGCHECK™ development program evaluating tagmokitug in combination with toripalimab. The data showed encouraging anti-tumor activity across multiple solid tumors, particularly in esophageal squamous cell carcinoma (ESCC). In first-line ESCC, the combination demonstrated a 75% confirmed overall response rate (cORR) irrespective of PD-L1 status, increasing to 89% post-data cutoff. Second-line ESCC also showed durable clinical benefit. The company plans to expand enrollment in ESCC cohorts based on these positive interim findings and a manageable safety profile.

Coherus Oncology reported a net loss of $(20.6) million for Q2 2026, a significant decline from a net income of $297.8 million in Q2 2025, primarily due to reduced income from discontinued operations. Net revenue from continuing operations, driven by LOQTORZI sales, increased to $14.3 million. The company maintains $105.3 million in cash and marketable securities but anticipates needing additional funding for clinical trials and commercialization.

Coherus Oncology reported Q2 2026 financial results, with LOQTORZI net revenue reaching $13.6 million, a 37% increase year-over-year. The company significantly reduced its net loss from continuing operations to $(33.3) million, or $(0.22) per diluted share, compared to $(44.9) million in the prior year. Coherus also highlighted strong commercial performance for LOQTORZI and continued advancement of its oncology pipeline, with initial data readouts for Tagmokitug and Casdozokitug expected in the second half of 2026.

Coherus Oncology, Inc. announced that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026. Following the release, the management team will host a conference call and webcast at 5:00 p.m. Eastern Daylight Time to discuss the results and provide a general business update. A replay of the webcast will be accessible on the company's investor relations website.

Coherus Oncology, Inc. and Zumutor Biologics Inc. announced a clinical collaboration and supply agreement to conduct a Phase 1 trial. The study will evaluate ZM008, Zumutor's novel NK checkpoint antibody, in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab-tpzi). This trial, identified as NCT06451497, aims to enroll up to 45 patients with various solid tumors, including colorectal, head and neck, non-small cell lung cancer, and urothelial cancers. Coherus will provide LOQTORZI, while Zumutor will sponsor the trial, with both companies retaining commercial rights to their respective compounds.

Coherus Oncology, Inc. dismissed Ernst & Young LLP as its independent registered public accounting firm on June 12, 2026. The company subsequently appointed PricewaterhouseCoopers LLP to serve as its new auditor for the fiscal year ending December 31, 2026. EY's previous reports for 2024 and 2025 did not contain adverse opinions, though a material weakness in internal controls was noted for 2024, which was remediated by 2025.

Coherus Oncology reported a net revenue of $12.31 million for the first quarter of 2026, a significant increase from $7.60 million in the prior year. The company's net loss improved to $(38.33) million, or $(0.28) per share, compared to a net loss of $(56.57) million, or $(0.49) per share, in Q1 2025. This improvement was supported by increased sales of LOQTORZI and a public offering that generated $53.65 million in net proceeds, boosting cash reserves despite higher operating cash burn.

Coherus Oncology reported a net loss from continuing operations of $36.9 million, or $(0.27) per share, for Q1 2026, an improvement from a $47.4 million loss in Q1 2025. LOQTORZI net revenue increased 61% year-over-year to $11.8 million, despite a 5% sequential decrease attributed to weather and seasonality. The company also completed patient accrual for its 1L HCC Phase 2 trial for casdozokitug and advanced its tagmokitug program, with multiple data readouts expected in 2026.

Coherus Oncology reported Q1 2026 net revenue from continuing operations of $12.3 million, an increase from $7.6 million in Q1 2025. LOQTORZI net revenue was $11.8 million, up 61% year-over-year but down 5% quarter-over-quarter due to seasonal factors. The company posted a net loss from continuing operations of $(36.9) million, or $(0.27) per share, an improvement from $(47.4) million in the prior year. Coherus ended the quarter with $167.0 million in cash, cash equivalents, and marketable securities, and completed patient accrual for the 1L HCC Phase 2 trial of casdozokitug, with data expected mid-year.

Coherus Oncology, Inc. announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the financial results and provide a general business update. A webcast replay and related materials will be accessible on the company's investor relations website.